Emerging as a promising development in the battle against obesity, this medication is generating considerable attention . This treatment combines effects of two known GLP-1 receptor agonists, liraglutide, plus an new glucose-dependent peptide component. Preliminary patient results have indicated significant weight loss in individuals with excessive